StockData
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP) stock

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$40.15−0.22 (-0.54%)

Close on Nov 17, 2026Market cap $3.88BP/E –Yield –

CRISPR Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

CRISPR Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$369.58M. For fiscal 2025 it was -$345.01M. The highest annual figure on record is $538.97M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$345.01M–
FY2024Dec 31, 2024-$142.77M–
FY2023Dec 31, 2023-$260.38M–
FY2022Dec 31, 2022-$495.74M-192.0%
FY2021Dec 31, 2021$538.97M–
FY2020Dec 31, 2020-$238.37M-520.6%
FY2019Dec 31, 2019$56.68M–
FY2018Dec 31, 2018-$96.24M–
FY2017Dec 31, 2017-$70.09M–
FY2016Dec 31, 2016-$52.86M-188.9%
FY2015Dec 31, 2015$59.43M–
FY2014Dec 31, 2014-$4.79M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$83.50M–
Q1 FY2026Mar 31, 2026-$108.90M–
Q4 FY2025Dec 31, 2025-$92.55M–
Q3 FY2025Sep 30, 2025-$84.63M–
Q2 FY2025Jun 30, 2025-$113.88M–
Q1 FY2025Mar 31, 2025-$53.95M-149.2%
Q4 FY2024Dec 31, 2024-$50.03M–
Q3 FY2024Sep 30, 2024-$106.91M–
Q2 FY2024Jun 30, 2024-$95.58M–
Q1 FY2024Mar 31, 2024$109.75M+1147.3%
Q4 FY2023Dec 31, 2023-$96.07M–
Q3 FY2023Sep 30, 2023-$39.86M–
Q2 FY2023Jun 30, 2023-$133.25M–
Q1 FY2023Mar 31, 2023$8.80M–
Q4 FY2022Dec 31, 2022-$113.33M–
Q3 FY2022Sep 30, 2022-$105.22M–
Q2 FY2022Jun 30, 2022-$141.96M-117.6%
Q1 FY2022Mar 31, 2022-$135.24M–
Q4 FY2021Dec 31, 2021-$86.04M–
Q3 FY2021Sep 30, 2021-$81.33M–
Q2 FY2021Jun 30, 2021$807.00M–
Q1 FY2021Mar 31, 2021-$100.66M–
Q4 FY2020Dec 31, 2020-$81.21M-2505.6%
Q3 FY2020Sep 30, 2020-$75.70M-156.7%
Q2 FY2020Jun 30, 2020-$29.28M–
Q1 FY2020Mar 31, 2020-$52.18M–
Q4 FY2019Dec 31, 2019$3.38M–
Q3 FY2019Sep 30, 2019$133.42M–
Q2 FY2019Jun 30, 2019-$36.38M–
Q1 FY2019Mar 31, 2019-$43.74M–
Q4 FY2018Dec 31, 2018-$28.37M–
Q3 FY2018Sep 30, 2018-$19.96M–
Q2 FY2018Jun 30, 2018-$25.22M–
Q1 FY2018Mar 31, 2018-$22.69M–
Q4 FY2017Dec 31, 2017-$14.84M–
Q3 FY2017Sep 30, 2017-$15.87M–
Q2 FY2017Jun 30, 2017-$15.97M–
Q1 FY2017Mar 31, 2017-$23.41M–
Q4 FY2016Dec 31, 2016-$16.97M–
Q3 FY2016Sep 30, 2016-$12.28M–

More CRISPR Therapeutics figures

See a number that looks wrong?